Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Authors
Neoptolemos, JMoore, M
Cox, T
Valle, Juan W
Palmer, D
McDonald, A
Carter, R
Tebbutt, N
Dervenis, C
Smith, D
Glimelius, B
Charnley, R
Lacaine, F
Scarfe, A
Middleton, M
Anthoney, A
Ghaneh, P
Halloran, C
Lerch, M
Oláh, A
Rawcliffe, C
Verbeke, C
Campbell, F
Büchler, M
Affiliation
Institute of Translational Medicine, Liverpool Cancer Trials Unit, Liverpool Cancer Research United Kingdom Centre, University of Liverpool, Liverpool, England, United Kingdom. j.p.neoptolemos@liverpool.ac.ukIssue Date
2012-07-11
Metadata
Show full item recordAbstract
Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas.Citation
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. 2012, 308 (2):147-56 JAMAJournal
JAMADOI
10.1001/jama.2012.7352PubMed ID
22782416Type
ArticleLanguage
enISSN
1538-3598ae974a485f413a2113503eed53cd6c53
10.1001/jama.2012.7352